Receptor tyrosine kinase inhibitors in cancer

被引：26

作者：

Ebrahimi, Nasim ^{[1
]}

Fardi, Elmira ^{[2
]}

Ghaderi, Hajarossadat ^{[3
]}

Palizdar, Sahar ^{[4
]}

Khorram, Roya ^{[5
]}

Vafadar, Reza ^{[6
]}

Ghanaatian, Masoud ^{[7
]}

Rezaei-Tazangi, Fatemeh ^{[8
]}

Baziyar, Payam ^{[9
]}

Ahmadi, Amirhossein ^{[10
]}

Hamblin, Michael R. ^{[11
]}

Aref, Amir Reza ^{[12
,13
]}

机构：

[1] Univ Isfahan, Fac Sci & Technol, Dept Cell & Mol Biol & Microbiol, Genet Div, Esfahan, Iran

[2] Islamic Azad Univ Tehran, Med Branch, Tehran, Iran

[3] Pasteur Inst Iran, Lab Regenerat & Med Innovat, Tehran, Iran

[4] Islamic Azad Univ Tehran East Branch, Fac Basic Sci, Div Microbiol, Tehran, Iran

[5] Shiraz Univ Med Sci, Bone & Joint Dis Res Ctr, Dept Orthoped Surg, Shiraz, Iran

[6] Kerman Univ Med Sci, Dept Orthopead Surg, Kerman, Iran

[7] Univ Toulouse III Paul Sabatier, Master Bio Sante Parcours Toulouse Grad Sch Canc A, Toulouse, France

[8] Fasa Univ Med Sci, Sch Med, Dept Anat, Fasa, Iran

[9] Univ Mazandaran, Fac Basic Sci, Dept Mol & Cell Biol, Babolsar, Iran

[10] Persian Gulf Univ, Fac Nano & Bio Sci & Technol, Dept Biol Sci & Technol, Bushehr 75169, Iran

[11] Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, ZA-2028 Doornfontein, South Africa

[12] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[13] Xsphera Biosci, Translat Med Grp, 6 Tide St, Boston, MA 02210 USA

来源：

CELLULAR AND MOLECULAR LIFE SCIENCES | 2023年 / 80卷 / 04期

基金：

美国国家卫生研究院;

关键词：

Targeted therapy; Immune therapy; RTK inhibitors; Drug resistance; Cancer therapy; RENAL-CELL CARCINOMA; GROWTH-FACTOR; LUNG-CANCER; THERAPEUTIC TARGET; DRUG-RESISTANCE; PHASE-III; HEPATOCELLULAR-CARCINOMA; ONCOGENIC ACTIVATION; ACQUIRED-RESISTANCE; MOLECULAR TARGET;

D O I：

10.1007/s00018-023-04729-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) some of which have entered clinical application. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential effects of combination drug therapy (including chemotherapy or immunotherapy agents with one RTKI or multiple RTKIs) especially for drug resistant cancers.

引用

页数：18

共 50 条

[21] Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
Ocana, Alberto
Serrano, Rosario
Calero, Raul
Pandiella, Atanasio
CURRENT DRUG TARGETS, 2009, 10 (06) : 575 - 576
[22] Tyrosine kinase inhibitors in breast cancer (Review)
Iancu, George
Serban, Dragos
Badiu, Cristinel Dumitru
Tanasescu, Ciprian
Tudosie, Mihai Silviu
Tudor, Corneliu
Costea, Daniel Ovidiu
Zgura, Anca
Iancu, Raluca
Vasile, Danut
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 23 (02)
[23] Emerging tyrosine kinase inhibitors for esophageal cancer
Ku, Geoffrey Y.
Ilson, David H.
EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (02) : 219 - 230
[24] Tyrosine kinase inhibitors to treat liver cancer
Huynh, Hung
EXPERT OPINION ON EMERGING DRUGS, 2010, 15 (01) : 13 - 26
[25] Role of tyrosine kinase inhibitors in cancer therapy
Arora, A
Scholar, EM
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03): : 971 - 979
[26] Protein tyrosine kinase inhibitors in cancer therapy
Boutayeb, S.
Zakkouri, F. Z.
Aitelhaj, M.
Mesmoudi, M.
Boutayeb, A.
Boutayeb, W.
Mrabti, H.
Errihani, H.
PATHOLOGIE BIOLOGIE, 2012, 60 (04): : 229 - 233
[27] EGFR tyrosine kinase inhibitors in the treatment of cancer
Barker, AJ
MEDICINAL CHEMISTRY INTO THE MILLENNIUM, 2001, (264): : 140 - 147
[28] Protein tyrosine kinase inhibitors in cancer treatment
Traxler, PM
EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (06) : 571 - 588
[29] Fasting plus tyrosine kinase inhibitors in cancer
Caffa, Irene
Longo, Valter D.
Nencioni, Alessio
AGING-US, 2015, 7 (12): : 1026 - 1027
[30] Current landscape of tropomyosin receptor tyrosine kinase inhibitors
El-Nassan, Hala B.
FUTURE MEDICINAL CHEMISTRY, 2024,

← 1 2 3 4 5 →